• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Successful Treatment of Refractory B-cell Lymphomas with CAR T-Cell Therapy

January 3, 2018

Chimeric antigen receptor (CAR) T-cell therapy has been shown to successfully treat refractory B-cell lymphomas. Two new studies published in The New England Journal of Medicine confirm that CAR T-cell therapy can be used to treat B-cell lymphoma patients who have not responded to standard therapies. Neelapu et al. led a phase 2 trial (ZUMA-1) of 111 B-cell lymphoma patients at 22 medical institutions. CAR T-cells were successfully engineered for 110 patients (99%). Of the 101 patients (91%) who received injections of CAR T-cells, 54% had a complete response rate. Similarly, Schuster et al. observed a complete response rate of 57% among 28 refractory B-cell lymphoma patients. Many patients experienced minor adverse events, such as myelosuppression and other neurological problems; however, severe cytokine-release syndrome occurred in 13-18% of the patients and 4 patients died (3 in the ZUMA-1 study). CAR T-cells are a promising new personalized therapy for B-cell lymphoma patients who have little choice after conventional therapies have failed.

References:

  1. Neelapu SS, Locke FL, Barlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory B-cell lymphoma. New England Journal of Medicine 2017;377:2531-44.
  2. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T-cells in refractory B-cell lymphomas. New England Journal of Medicine 2017;377:2545-54.
  3. Tran E, Longo DL, and Urba WJ. A milestone for CAR T cells. New England Journal of Medicine 2017;377: 2593-96.

Filed Under

  • Cell Therapy
  • News

Recommended

  • Transfusion Important for Treatment of Warm Autoimmune Hemolytic Anemia

  • Serological Screening of Blood Donations Suggests SARS-CoV-2 May Have Been Introduced in the US before January 2020

  • New AABB Guidelines for Red Blood Cell Storage and Transfusion Thresholds

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Blood Transfusion Strategies for Major Trauma

  • Storage Duration Affects Hematological and Metabolic Parameters in Patients with Sickle Cell Disease

  • Syphilis Infections Among US Blood Donors

  • RBCs with Reduced Deformability are Removed from Circulation

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley